SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

22 May 2024 Evaluate
The sales for the March 2024 quarter moved up 49.58% to Rs. 11748.30 millions as compared to Rs. 7854.22 millions during the corresponding quarter last year.The Net Profit of the company vaulted to 305.79% to Rs. 3214.11  millions from Rs. 792.06 millions in the previous quarter.OP of the company witnessed a marginal growth to 4797.85 millions from 2080.92 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 11748.30 7854.22 49.58 41674.28 36165.28 15.23 41674.28 36165.28 15.23
Other Income 469.55 389.39 20.59 1666.66 2404.64 -30.69 1666.66 2404.64 -30.69
PBIDT 4797.85 2080.92 130.56 15754.47 12590.13 25.13 15754.47 12590.13 25.13
Interest 45.34 21.81 107.89 78.43 74.14 5.79 78.43 74.14 5.79
PBDT 4752.51 1494.50 218.00 15676.04 11951.38 31.17 15676.04 11951.38 31.17
Depreciation 425.63 375.42 13.37 1621.07 1467.36 10.48 1621.07 1467.36 10.48
PBT 4326.88 1119.08 286.65 14054.97 10484.02 34.06 14054.97 10484.02 34.06
TAX 1112.77 327.02 240.28 3621.72 2725.76 32.87 3621.72 2725.76 32.87
Deferred Tax 105.98 -104.98 -200.95 246.84 -27.99 -981.89 246.84 -27.99 -981.89
PAT 3214.11 792.06 305.79 10433.25 7758.26 34.48 10433.25 7758.26 34.48
Equity 164.71 164.70 0.01 164.71 164.70 0.01 164.71 164.70 0.01
PBIDTM(%) 40.84 26.49 54.14 37.80 34.81 8.59 37.80 34.81 8.59

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×